We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




ApoB Protein Testing More Accurately Predicts Heart Disease Risk than Testing for Cholesterol Alone

By LabMedica International staff writers
Posted on 07 Mar 2023
Print article
Image: ApoB may be a more accurate risk predictor of atherosclerotic cardiovascular disease (Photo courtesy of Intermountain Health)
Image: ApoB may be a more accurate risk predictor of atherosclerotic cardiovascular disease (Photo courtesy of Intermountain Health)

As part of the annual physical exam, individuals are typically tested for their levels of HDL (the good) and LDL (the bad) cholesterol to assess their risk for heart disease. However, recent research has raised questions about the accuracy of these standard tests in predicting heart disease risk. Instead, emerging data suggest that testing for levels of Apolipoprotein B-100 (ApoB), a protein responsible for transporting fat molecules including LDL cholesterol - notoriously known as the "bad cholesterol" - throughout the body, may be a more precise indicator of atherosclerotic cardiovascular disease.

In a new study presented at the 2023 American College of Cardiology annual Scientific Sessions in New Orleans, researchers from Intermountain Health (Salt Lake City, UT, USA) found that ApoB testing can help identify patients who may continue to face a higher risk for a cardiovascular event, despite their normal LDL cholesterol levels. ApoB testing remains fairly uncommon, but is on the rise. ApoB levels measure atherogeneic particle numbers, and several studies suggest that particle numbers are superior than cholesterol levels as risk predictors of disease. The better assessment of particle numbers could make ApoB better at evaluating risk, particularly for patients having normal LDL cholesterol levels, including those with metabolic syndrome, like diabetes or prediabetes or low HDL and high triglyceride levels.

The researchers conducted a retrospective study by analyzing electronic health records of patients from 2010 to February 2022. The study revealed that the number of Apo B tests administered increased from 29 cases in 2010 to 131 in 2021. Additionally, the team observed a positive correlation between ApoB and LDL cholesterol levels, though the ApoB/LDL cholesterol ratio rose as LDL cholesterol decreased. This indicated a high number of atherogenic small, dense LDL particles characterized by smaller amounts of LDL cholesterol per particle. However, the researchers do not expect ApoB to replace standard HDL and LDL testing soon, as it is costlier and not yet firmly established in the healthcare system. Nevertheless, clinicians should increasingly consider ApoB testing a valuable tool for refining cardiovascular risk, particularly in specific patient groups.

“Testing for ApoB doesn’t tell you how much cholesterol a patient has, but instead it measures the number of particles that carry it,” said Jeffrey L. Anderson, Intermountain Health cardiologist and principal investigator of the study. “While it’s still not a commonly ordered test, we found that it’s both being used more often, and it could lead to a more accurate way to test for lipoprotein-related risk than how we do it now,”

Related Links:
Intermountain Health

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Uric Acid and Blood Glucose Meter
URIT-10

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.